论文部分内容阅读
目的观察孟鲁司特治疗节段性性支原体肺炎对肺功能的影响。方法回顾性分析120例节段性支原体肺炎患儿的临床资料。结果孟鲁司特组与对照组在治疗3周后的肺功能指标FEV1、FEV1/FVC%、PEF、FEF25%-75%、FEF25%、FEF50%、FEF75%差异具有统计学意义(P<0.05),孟鲁司特组肺功能指标改善较对照组明显,治疗后6个月,FEF75%差异有统计学意义(P<0.05)。结论孟鲁司特治疗节段性支原体肺炎能改善患儿的肺功能,未见不良反应,值得临床推广应用。
Objective To observe the effect of montelukast on mycoplasma pneumonia in patients with segmental mycoplasma pneumonia. Methods A retrospective analysis of 120 cases of mycoplasma pneumonia in children with clinical data. Results The FEV1, FEV1 / FVC%, PEF, FEF25% -75%, FEF25%, FEF50%, FEF75% of the montelukast group and the control group after 3 weeks of treatment were significantly different (P <0.05 ). The improvement of lung function in montelukast group was more obvious than that in control group. The difference of FEF75% at 6 months after treatment was statistically significant (P <0.05). Conclusion Montelukast treatment of mycoplasma pneumoniae can improve children’s lung function, no adverse reactions, it is worthy of clinical application.